Researcher.Life Logo

EJNMMI Radiopharmacy and Chemistry : Impact Factor & More

eISSN: 2365-421XpISSN: 2365-421X
JournalOpen Access

Aims and Scope of EJNMMI Radiopharmacy and Chemistry

EJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide-based therapeutic agents for application in nuclear medicine and molecular imaging. The journal provides a platform for chemists, pharmacists and basic scientists to present their views and scientific work. In addition, the journal provides insight into novel concepts of imaging or radionuclide-based therapeutic agent applications of relevance for the whole molecular imaging community. The journal reports original research articles, review papers, guidelines on the application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in the form of guidelines or position papers. Less

Key Metrics

CiteScore
2
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on EJNMMI Radiopharmacy and Chemistry

EJNMMI Radiopharmacy and Chemistry Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher Springer Nature
Language English
Frequency Continuous publication
Article Processing ChargesGBP 1190 | USD 1890
Publication Time5
Editorial Review ProcessBlind peer review
General Details
LanguageEnglish
Society/Institute/SponsorEuropean Association of Nuclear Medicine (EANM)
FrequencyContinuous publication
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 5
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessBlind peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY
OA statementVisit website
View less

Planning to publish in EJNMMI Radiopharmacy and Chemistry ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in EJNMMI Radiopharmacy and Chemistry

Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art.
  • 26 Apr 2026
  • EJNMMI radiopharmacy and chemistry
Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.
  • 21 Apr 2026
  • EJNMMI radiopharmacy and chemistry
Optimization of automated radiosynthesis method for [18F]AlF-NOTA-Octreotide and PET/CT imaging in neuroendocrine neoplasms.
  • 21 Apr 2026
  • EJNMMI radiopharmacy and chemistry
A 3D co-culture model with fibroblast-restricted FAP expression for cancer therapy using [212Pb]Pb-FAPI-46.
  • 18 Apr 2026
  • EJNMMI radiopharmacy and chemistry
Radiolabeling efficiency of FENTA chelators and stability of their terbium-161, lutetium-177 and bismuth-213 complexes.
  • 7 Apr 2026
  • EJNMMI radiopharmacy and chemistry
Comparison of two 18F-fluorinated glycopeptides for PET imaging of the functional liver mass.
  • 4 Apr 2026
  • EJNMMI radiopharmacy and chemistry
Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art.
  • 26 Apr 2026
  • EJNMMI radiopharmacy and chemistry
Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.
  • 21 Apr 2026
  • EJNMMI radiopharmacy and chemistry
Optimization of automated radiosynthesis method for [18F]AlF-NOTA-Octreotide and PET/CT imaging in neuroendocrine neoplasms.
  • 21 Apr 2026
  • EJNMMI radiopharmacy and chemistry
A 3D co-culture model with fibroblast-restricted FAP expression for cancer therapy using [212Pb]Pb-FAPI-46.
  • 18 Apr 2026
  • EJNMMI radiopharmacy and chemistry
Radiolabeling efficiency of FENTA chelators and stability of their terbium-161, lutetium-177 and bismuth-213 complexes.
  • 7 Apr 2026
  • EJNMMI radiopharmacy and chemistry
Comparison of two 18F-fluorinated glycopeptides for PET imaging of the functional liver mass.
  • 4 Apr 2026
  • EJNMMI radiopharmacy and chemistry

FAQs on EJNMMI Radiopharmacy and Chemistry